BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 28190310)

  • 1. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 2. [Establishment and verification of detecting multiple biomarkers for ovarian cancer by suspension array technology].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li DR; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Oct; 51(10):765-772. PubMed ID: 27788745
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.
    Mao L; Tang Y; Deng MJ; Huang CT; Lan D; Nong WZ; Li L; Wang Q
    J Clin Lab Anal; 2022 Feb; 36(2):e24232. PubMed ID: 34995016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
    Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
    Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.
    Zohny SF; Fayed ST
    Med Oncol; 2010 Dec; 27(4):1246-53. PubMed ID: 19937162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
    Wang Q; Zhang W; Li DR; Li L
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
    Onsrud M; Shabana A; Austgulen R
    Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.